Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images

Topics in Magnetic Resonance Imaging

Volumn 26, Issue 1, 2017, Pages 43-53

  Abrol, Srishti ^a   Kotrotsou, Aikaterini ^a   Salem, Ahmed ^a   Zinn, Pascal O ^b   Colen, Rivka R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

brain tumor; imaging; imaging genomics; radiogenomics; radiomics

Indexed keywords

BRAIN CANCER; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; DATA BASE; DATA MINING; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DIGITAL IMAGING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION; INFORMATION PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; RADIOLOGY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKFLOW; BRAIN NEOPLASMS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MOLECULAR IMAGING; PERSONALIZED MEDICINE; PROCEDURES;

GENETIC MARKER; TUMOR MARKER;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; PHENOTYPE; PRECISION MEDICINE; RADIOLOGY;

EID: 85009373564     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0000000000000117     Document Type: Review

References (132)

1. Jenkinson MD, Du Plessis DG, Walker C, Smith TS. Advanced MRI in the management of adult gliomas. Br J Neurosurg. 2007;21:550-561.
2. Kao HW, Chiang SW, Chung HW, et al. Advanced MR imaging of gliomas: an update. Biomed Res Int. 2013;2013:970586.
3. Kimura M, da Cruz Jr LC. Multiparametric MR imaging in the assessment of brain tumors. Magn Reson Imaging Clin N Am. 2016;24:87-122.
4. Choudhri AF, Siddiqui A, Klimo Jr P, Boop FA. Intraoperative MRI in pediatric brain tumors. Pediatr Radiol. 2015;45(Suppl 3):S397-405.
5. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234-1248.
6. Borsook D, Beccera LR, Bullmore E, Hargreaves RJ. Implications for disease and therapy. In: Bullmore E, editor. Imaging in CNS Drug Discovery and Development. New York: Springer; 2009.
7. Zinn PO, Colen RR. Imaging genomic mapping in glioblastoma. Neurosurgery. 2013;60(Suppl 1):126-130.
8. Gutman DA, Cooper LA, Hwang SN, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013;267:560-569.
9. Wangaryattawanich P, Hatami M, Wang J, et al. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro Oncol. 2015;17:1525-1537.
10. Sala E, Mema E, Himoto Y, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 2016 [Epub ahead of print].
11. Kuo MD, Gollub J, Sirlin CB, et al. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:821-831.
12. Teruel JR, Heldahl MG, Goa PE, et al. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. NMR Biomed. 2014;27:887-896.
13. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
14. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2000;87:881-886.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
16. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
17. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e270-e278.
18. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
19. Gatenby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology. 2013;269:8-15.
20. Hatt M, Tixier F, Pierce L, et al. Characterization of PET/CT images using texture analysis: the past, the present.. any future? Eur J Nucl Med Mol Imaging. 2017;44:151-165.
21. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
22. Grove O, Berglund AE, Schabath MB, et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One. 2015;10:e0118261.
23. Hu LS, Ning S, Eschbacher JM, et al. Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLoS One. 2015;10:e0141506.
24. Hu LS, Ning S, Eschbacher JM, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol;. 2016 [Epub ahead of print].
25. Parker NR, Hudson AL, Khong P, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016;6:22477.
26. Zang Y, Metz LM. 1.5T versus 3.0T MRI texture analysis in the normal appearing white matter of multiple sclerosis patients. Proc Intl Soc Mag Reson Med. 2012;20.
27. Loizou CP, Pantziaris M, Pattichis CS, Seimenis I. Brain MR image normalization in texture analysis of multiple sclerosis. J Biomedical Graphics Comput. 2013;3. DOI: 10.5430/jbgc.v3n1p20; URL: http://dx.doi.org/10.5430/jbgc.v3n1p20.
28. Depeursinge A, Foncubierta-Rodriguez A, Van De Ville D, Muller H. Three-dimensional solid texture analysis in biomedical imaging: review and opportunities. Med Image Anal. 2014;18:176-196.
29. Mayerhoefer ME, Szomolanyi P, Jirak D, et al. Effects of MRI acquisition parameter variations and protocol heterogeneity on the results of texture analysis and pattern discrimination: an application-oriented study. Med Phys. 2009;36:1236-1243.
30. Nash DB. Harnessing the power of big data in healthcare. Am Health Drug Benefits. 2014;7:69-70.
31. Hajek M, Dezortova M, Materka A, Lerski R. Texture Analysis for Magnetic Resonance Imaging. Prague: Med4publishing; 2006.
32. Upadhyay N, Waldman AD. Conventional MRI evaluation of gliomas. Brit J Radiol. 2011;84(Spec Iss 2):S107-S111.
33. Olabarriaga SD, Smeulders AW. Interaction in the segmentation of medical images: a survey. Med Image Anal. 2001;5:127-142.
34. Gordillo N, Montseny E, Sobrevilla P. State of the art survey on MRI brain tumor segmentation. Magn Reson Imaging. 2013;31:1426-1438.
35. Despotovic I, Goossens B, Philips W. MRI segmentation of the human brain: challenges, methods, and applications. Comput Math Methods Med. 2015;2015:450341.
36. Helms G. Segmentation of human brain using structural MRI. MAGMA. 2016;29:111-124.
37. Warfield SK, Zou KH, Wells WM. Validation of image segmentation by estimating rater bias and variance. Philos Trans A Math Phys Eng Sci. 2008;366:2361-2375.
38. Khalilzadeh MM, Fatemizadeh E, Behnam H. Automatic segmentation of brain MRI in high-dimensional local and non-local feature space based on sparse representation. Magn Reson Imaging. 2013;31:733-741.
39. Atkins MS, Mackiewich BT. Fully automatic segmentation of the brain in MRI. IEEE Trans Med Imaging. 1998;17:98-107.
40. Weizman L, Sira LB, Joskowicz L, et al. Semiautomatic segmentation and follow-up of multicomponent low-grade tumors in longitudinal brain MRI studies. Med Phys. 2014;41:052303.
41. Zinn PO, Mahajan B, Sathyan P, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6:e25451.
42. Nicolasjilwan M, Hu Y, Yan C, et al. Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. J Neuroradiol. 2015;42:212-221.
43. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563-577.
44. Pratt WK. Image Segmentation. Digital Image Processing: PIKS Inside. 3rd ed. New York: John Wiley and Sons, Inc; 1991, 551-587.
45. Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22:1081-1088.
46. Hassan I, Kotrotsou A, Bakhtiari AS, et al. Radiomic texture analysis mapping predicts areas of true functional MRI activity. Sci Rep. 2016;6:25295.
47. Kassner A, Thornhill RE. Texture analysis: a review of neurologic MR imaging applications. AJNR Am J Neuroradiol. 2010;31:809-816.
48. Papoulis A. Random Variables, and Stochastic Processes. New York: McGraw-Hill; 1990.
49. Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Transact Syst Man Cybernet. 1973;SMC-3: 610-621.
50. Soh LK, Tsatsoulis C. Texture analysis of SAR sea ice imagery using gray level co-occurrence matrices. IEEE Transact Geosci Remote Sensing. 1999;37:780-795.
51. Kotrotsou A, Zinn PO, Colen RR. Radiomics in brain tumors: an emerging technique for characterization of tumor environment. Magn Reson Imaging Clin N Am 2016;24:719-729.
52. Lam SW. Texture feature extraction using gray level gradient based co-occurence matrices. Systems, Man, and Cybernetics, 1996. IEEE International Conference on 1996;1:267-71.
53. Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging. 2013;13:400-406.
54. Guo X, Liu X, Wang H, et al. Enhanced CTimages by the Wavelet transform improving diagnostic accuracy of chest nodules. J Digit Imaging. 2011;24:44-49.
55. Fayyad UM, Piatetsky-Shapiro G, Smyth P. From data mining to knowledge discovery: an overview. In: Usama MF, et al., eds. Advances in Knowledge Discovery and Data Mining. American Association for Artificial Intelligence; 1996:1-34.
56. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32:733-743.
57. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373-1379.
58. Parmar C, Grossmann P, Bussink J, et al. Machine learning methods for quantitative radiomic biomarkers. Sci Rep. 2015;5:13087.
59. Kotsiantis SB, Zaharakis ID, et al. Machine learning: a review of classification and combining techniques. Artif Intell Rev. 2006;159-190. DOI 10.1007/s10462-007-9052-3.
60. Hawkins SH. Predicting outcomes of nonsmall cell lung cancer using CT image features. IEEE Access. 2014;2:1418-1426.
61. Basu, S. et al. in Systems, Man, and Cybernetics (SMC), 2011 IEEE International Conference on. 1306-1312 (IEEE).
62. Parmar C, Grossmann P, Rietveld D, et al. Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. Front Oncol. 2015;5.
63. Schad LR, Bluml S, Zuna I. MR tissue characterization of intracranial tumors by means of texture analysis. Magn Reson Imaging. 1993;11:889-896.
64. Kjaer L, Ring P, Thomsen C, Henriksen O. Texture analysis in quantitative MR imaging. Tissue characterisation of normal brain and intracranial tumours at 1.5 T. Acta Radiol. 1995;36:127-135.
65. Zacharaki EI, Wang S, Chawla S, et al. Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme. Magn Reson Med. 2009;62:1609-1618.
66. Pallavi T, Prateek P, Lisa R, et al. Texture descriptors to distinguish radiation necrosis from recurrent brain tumors on multi-parametric MRI. Proc SPIE Int Soc Opt Eng. 2014;9035:90352B.
67. Georgiadis P, Kostopoulos S, Cavouras D, et al. Quantitative combination of volumetric MR imaging and MR spectroscopy data for the discrimination of meningiomas from metastatic brain tumors by means of pattern recognition. Magn Reson Imaging. 2011;29:525-535.
68. Wang Q, Karamani Liacouras E, Miranda E, et al. Classification of brain tumors using MRI and MRS data. Proc of SPIE. 2007;6514:65140S1-65140S8.
69. Devos A, Simonetti AW, van der Graff M, et al. The use of multivariate MR imaging intensities versus metabolic data from MR spectroscopic imaging for brain tumour classification. J Magn Reson. 2005;173:218-228.
70. Eliat P-A, Olivie D, Saikali S, et al. Can dynamic contrast-enhanced magnetic resonance imaging combined with texture analysis differentiate malignant glioneuronal tumors from other glioblastoma? Neurol Res Int. 2012;2012:195176.
71. Fetit AE, Novak J, Rodriguez D, et al. 3D texture analysis of heterogeneous MRI data for diagnostic classification of childhood brain tumours. Stud Health Technol Inform. 2015;213:19-22.
72. Pierpaoli C. Quantitative brain MRI. Topics Magn Reson Imaging. 2010;21:63-163.
73. Brant-Zawadzki M, Badami JP, Mills CM, et al. Primary intracranial tumor imaging: a comparison of magnetic resonance and CT. Radiology. 1984;150:435-440.
74. Guzman-De-Villoria JA, Mateos-Perez JM, Fernandez-Garcia P, et al. Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging. 2014;14:35.
75. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg. 1993;79:533-536.
76. Wong ET, Jackson EF, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998;50:777-781.
77. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol. 2000;174:1147-1157.
78. Butowski NA. Epidemiology and diagnosis of brain tumors. Continuum (Minneap Minn). 2015;21:301-313.
79. Chen J, Xia J, Zhou YC, et al. [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma]. Zhonghua Zhong Liu Za Zhi. 2005;27:309-311.
80. Kang Y, Choi SH, Kim YJ, et al. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard-or high-b-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology. 2011;261:882-890.
81. Ryu YJ, Choi SH, Park SJ, et al. Glioma: application of whole-tumor texture analysis of diffusion-weighted imaging for the evaluation of tumor heterogeneity. PLoS One. 2014;9:e108335.
82. Brynolfsson P, Nilsson D, Henriksson R, et al. ADC texture-an imaging biomarker for high-grade glioma? Med Phys. 2014;41:101903.
83. Rodriguez Gutierrez D, Awwad A, Meijer L, et al. Metrics and textural features of MRI diffusion to improve classification of pediatric posterior fossa tumors. Am J Neuroradiol. 2014;35:1009-1015.
84. Korfiatis P, Erickson B. The basics of diffusion and perfusion imaging in brain tumors. Appl Radiol. 2014;43:22-29.
85. Joint Head and Neck Radiotherapy-MRI Development Cooperative. Neck radiotherapy, dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. Sci Rep. 2016;6:29864.
86. Wintermark M, Sesay M, Barbier E, et al. Comparative overview of brain perfusion imaging techniques. J Neuroradiol. 2005;32:294-314.
87. Filice S, Crisi G. Dynamic contrast-enhanced perfusion MRI of high grade brain gliomas obtained with arterial or venous waveform input function. J Neuroimaging. 2016;26:124-129.
88. Sourbron S, Ingrisch M, Siefert A, et al. Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med. 2009;62:205-217.
89. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91-101.
90. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
91. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology. 2002;223:11-29.
92. Dangouloff-Ros V, Deroulers C, Foissac F, et al. Arterial spin labeling to predict brain tumor grading in children: correlations between histopathologic vascular density and perfusion MR imaging. Radiology. 2016;281:553-566.
93. Santarosa C, Castellano A, Conte GM, et al. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. Eur J Radiol. 2016;85:1147-1156.
94. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490-498.
95. Lee J, Jain R, Khalil K, et al. Texture feature ratios from rCBV maps of perfusion MRI are associated with patient survival in glioblastoma. AJNR Am J Neuroradiol. 2016;37:37-43.
96. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998.
97. Mouthuy N, Cosnard G, Abarca-Quinones J, Michoux N. Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases. J Neuroradiol. 2012;39:301-307.
98. Oz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270:658-679.
99. Warren KE, Frank JA, Black JL, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol. 2000;18:1020-1026.
100. Bulik M, Jancalek R, Vanicek J, et al. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 2013;115:146-153.
101. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q. 1994;10:191-247.
102. Andronesi OC, Loebel F, Bogner W, et al. Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2-hydroxyglutarate. Clin Cancer Res. 2016;22:1632-1641.
103. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18:624-629.
104. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107:197-205.
105. Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol. 2009;91:233-236.
106. Nachimuthu DS, Baladhandapani A. Multidimensional texture characterization: on analysis for brain tumor tissues using MRS and MRI. J Digit Imaging. 2014;27:496-506.
107. Ellingson BM. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr Neurol Neurosci Rep. 2015;15:506.
108. Zinn PO, Mahmood Z, Elbanan MG, Colen RR. Imaging genomics in gliomas. Cancer J. 2015;21:225-234.
109. Rao A, Rao G, Gutman DA, et al. A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma. J Neurosurg. 2016;124:1008-1017.
110. Colen R, Foster I, Gatenby R, et al. NCI Workshop Report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol. 2014;7:556-569.
111. Moton S, Elbanan M, Zinn O, Colen RR. Imaging genomics of glioblastoma: biology, biomarkers, and breakthroughs. Top Magn Reson Imaging. 2015;24:155-163.
112. Levner I, Drabycz S, Roldan G, et al. Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Comput Assist Interv. 2009;12(Pt 2):522-530.
113. Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398-1405.
114. Korfiatis P, Kline TL, Coufalova L, et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys. 2016;43:2835.
115. Zhang B, Chang K, Ramkissoon S, et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol;. 2016 [Epub ahead of print].
116. Brown R, Zlatescu M, Sijben A, et al. The useof magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res. 2008;14:2357-2362.
117. Zinn PO, Singh SK, Kotrotsou A, et al. 139 clinically applicable and biologically validated MRI radiomic test method predicts glioblastoma genomic landscape and survival. Neurosurgery. 2016;63(Suppl 1): 156-157.
118. Arnold SM, Patchell RA. Diagnosis and management of brain metastases. Hematol Oncol Clin North Am. 2001;15:1085-1107.
119. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579-592.
120. Wong J, Hird A, Kirou-Mauro A, et al. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol. 2008;15:25-45.
121. Nardone V, Tini P, Biondi M, et al. Prognostic value of MR imaging texture analysis in brain non-small cell lung cancer oligo-metastases undergoing stereotactic irradiation. Cureus. 2016;8:e584.
122. Li Z, Mao Y, Li H, et al. Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. Magn Reson Med. 2016;76:1410-1419.
123. Manyika J, Chui M, Brown B, et al. Big Data: The Next Frontier for Innovation, Competition and Productivity. Reportby McKinsey Global Institute, May 2011.
124. Kansagra AP, Yu JP, Chatterjee AR, et al. Big data and the future of radiology informatics. Acad Radiol. 2016;23:30-42.
125. Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2014;2:3.
126. Nilay D, Shah JP. Why Health Care May Finally Be Ready for Big Data. 2014. Available at: https://hbr.org/2014/12/why-health-care-may-finally-be-ready-for-big-data. Accessed December 3, 2014.
127. Siegel R, Desantis C, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
128. Feldman B, Martin EM, Skotnes T. Big data in healthcare hype and hope. October, 2012.
129. Marx V. Biology: the big challenges of big data. Nature. 2013;498:255-260.
130. Marr B. Big Data: 20 Mind-Boggling Facts Everyone Must Read. Available at: http://www.forbes.com/sites/bernardmarr/2015/09/30/big-data-20-mind-boggl ing-facts-everyone-must-read/#119f9e786c1d. Accessed September 30, 2015.
131. Bibault JE, Giraud P, Burgun A. Big data and machine learning in radiation oncology: stateof the art and future prospects. Cancer Lett 2016; 382:110-117.
132. Nelson B. Data sharing: empty archives. Nature. 2009;461:160-163.